Advertisement
Australia markets close in 4 hours 13 minutes

  • ALL ORDS

    8,033.80
    +31.00 (+0.39%)
     

  • ASX 200

    7,791.60
    +32.00 (+0.41%)
     

  • AUD/USD

    0.6626
    -0.0025 (-0.38%)
     

  • OIL

    82.09
    +0.35 (+0.43%)
     

  • GOLD

    2,330.70
    -5.90 (-0.25%)
     

  • Bitcoin AUD

    93,583.23
    +1,437.77 (+1.56%)
     

  • CMC Crypto 200

    1,293.44
    +27.29 (+2.16%)
     

  • AUD/EUR

    0.6196
    -0.0010 (-0.17%)
     

  • AUD/NZD

    1.0926
    -0.0001 (-0.01%)
     

  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     

  • NASDAQ

    19,789.03
    +37.98 (+0.19%)
     

  • FTSE

    8,179.68
    -45.65 (-0.55%)
     

  • Dow Jones

    39,164.06
    +36.26 (+0.09%)
     

  • DAX

    18,210.55
    +55.31 (+0.30%)
     

  • Hang Seng

    17,698.56
    -17.91 (-0.10%)
     

  • NIKKEI 225

    39,753.26
    +411.72 (+1.05%)
     

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Therapeutics N.V.
·2-min read
LAVA Therapeutics N.V.
LAVA Therapeutics N.V.

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

Presentation Details
Format: Fireside Chat
Date: Tuesday, June 25, 2024
Time: 9:30 AM ET

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date.

ADVERTISEMENT

About LAVA Therapeutics

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.

A Phase 1/2a dose escalation study (NCT05369000) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a study evaluating monotherapy and with interleukin-2 (IL-2). The Company is expanding the Phase 1/2a study to include a combination arm with KEYTRUDA®(pembrolizumab) through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, X, and YouTube.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA

Gammabody® is a registered trademark of LAVA Therapeutics N.V.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

LifeSci Advisors (IR/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com